To avoid muscle-related adverse events, choose statins carefully in patients receiving antiviral protease inhibitors


    loading  Checking for direct PDF access through Ovid

Abstract

The appropriate statin to treat co-morbid dyslipidaemia requires careful selection in patient with hepatitis C virus (HCV) infection receiving HCV protease inhibitors (e.g. telaprevir and boceprevir), and those with HIV-1 infection receiving ritonavir- or cobicistat-boosted HIV protease inhibitors. HCV and boosted-HIV protease inhibitors can increase the plasma concentrations of certain statins, thereby increasing the risk of the potential for statin-related myopathy.

    loading  Loading Related Articles